124 related articles for article (PubMed ID: 36635219)
1. Retinal ganglion cell loss is associated with future disability worsening in early relapsing-remitting multiple sclerosis.
Wauschkuhn J; Solorza Buenrostro G; Aly L; Asseyer S; Wicklein R; Hartberger JM; Ruprecht K; Mühlau M; Schmitz-Hübsch T; Chien C; Berthele A; Brandt AU; Korn T; Paul F; Hemmer B; Zimmermann HG; Knier B
Eur J Neurol; 2023 Apr; 30(4):982-990. PubMed ID: 36635219
[TBL] [Abstract][Full Text] [Related]
2. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
[TBL] [Abstract][Full Text] [Related]
3. Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome.
Zimmermann HG; Knier B; Oberwahrenbrock T; Behrens J; Pfuhl C; Aly L; Kaminski M; Hoshi MM; Specovius S; Giess RM; Scheel M; Mühlau M; Bellmann-Strobl J; Ruprecht K; Hemmer B; Korn T; Paul F; Brandt AU
JAMA Neurol; 2018 Sep; 75(9):1071-1079. PubMed ID: 29710121
[TBL] [Abstract][Full Text] [Related]
4. Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis.
Lin TY; Vitkova V; Asseyer S; Martorell Serra I; Motamedi S; Chien C; Ditzhaus M; Papadopoulou A; Benkert P; Kuhle J; Bellmann-Strobl J; Ruprecht K; Paul F; Brandt AU; Zimmermann HG
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34348969
[TBL] [Abstract][Full Text] [Related]
5. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.
Martinez-Lapiscina EH; Arnow S; Wilson JA; Saidha S; Preiningerova JL; Oberwahrenbrock T; Brandt AU; Pablo LE; Guerrieri S; Gonzalez I; Outteryck O; Mueller AK; Albrecht P; Chan W; Lukas S; Balk LJ; Fraser C; Frederiksen JL; Resto J; Frohman T; Cordano C; Zubizarreta I; Andorra M; Sanchez-Dalmau B; Saiz A; Bermel R; Klistorner A; Petzold A; Schippling S; Costello F; Aktas O; Vermersch P; Oreja-Guevara C; Comi G; Leocani L; Garcia-Martin E; Paul F; Havrdova E; Frohman E; Balcer LJ; Green AJ; Calabresi PA; Villoslada P;
Lancet Neurol; 2016 May; 15(6):574-84. PubMed ID: 27011339
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
[TBL] [Abstract][Full Text] [Related]
7. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis.
Gernert JA; Böhm L; Starck M; Buchka S; Kümpfel T; Kleiter I; Havla J
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629053
[TBL] [Abstract][Full Text] [Related]
8. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning.
Ratchford JN; Saidha S; Sotirchos ES; Oh JA; Seigo MA; Eckstein C; Durbin MK; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome SD; Balcer LJ; Frohman EM; Calabresi PA
Neurology; 2013 Jan; 80(1):47-54. PubMed ID: 23267030
[TBL] [Abstract][Full Text] [Related]
9. Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis.
Knier B; Leppenetier G; Wetzlmair C; Aly L; Hoshi MM; Pernpeintner V; Biberacher V; Berthele A; Mühlau M; Zimmer C; Hemmer B; Korn T
JAMA Neurol; 2017 Jul; 74(7):847-856. PubMed ID: 28460032
[TBL] [Abstract][Full Text] [Related]
10. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.
Saidha S; Sotirchos ES; Ibrahim MA; Crainiceanu CM; Gelfand JM; Sepah YJ; Ratchford JN; Oh J; Seigo MA; Newsome SD; Balcer LJ; Frohman EM; Green AJ; Nguyen QD; Calabresi PA
Lancet Neurol; 2012 Nov; 11(11):963-72. PubMed ID: 23041237
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.
Saidha S; Al-Louzi O; Ratchford JN; Bhargava P; Oh J; Newsome SD; Prince JL; Pham D; Roy S; van Zijl P; Balcer LJ; Frohman EM; Reich DS; Crainiceanu C; Calabresi PA
Ann Neurol; 2015 Nov; 78(5):801-13. PubMed ID: 26190464
[TBL] [Abstract][Full Text] [Related]
12. Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis.
Bsteh G; Hegen H; Altmann P; Auer M; Berek K; Di Pauli F; Haider L; Kornek B; Krajnc N; Leutmezer F; Macher S; Rommer P; Walchhofer LM; Zebenholzer K; Zulehner G; Deisenhammer F; Pemp B; Berger T
Eur J Neurol; 2023 Apr; 30(4):1025-1034. PubMed ID: 36719184
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis.
Cellerino M; Priano L; Bruschi N; Boffa G; Petracca M; Novi G; Lapucci C; Sbragia E; Uccelli A; Inglese M
J Neuroophthalmol; 2021 Sep; 41(3):329-334. PubMed ID: 33399416
[TBL] [Abstract][Full Text] [Related]
14. Association of retinal vessel pathology and brain atrophy in relapsing-remitting multiple sclerosis.
Romahn EF; Wiltgen T; Bussas M; Aly L; Wicklein R; Noll C; Berthele A; Dehmelt V; Mardin C; Zimmer C; Korn T; Hemmer B; Kirschke JS; Mühlau M; Knier B
Front Immunol; 2023; 14():1284986. PubMed ID: 38090586
[TBL] [Abstract][Full Text] [Related]
15. Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis.
Noll C; Hiltensperger M; Aly L; Wicklein R; Afzali AM; Mardin C; Gasperi C; Berthele A; Hemmer B; Korn T; Knier B
Front Immunol; 2022; 13():997043. PubMed ID: 36439131
[TBL] [Abstract][Full Text] [Related]
16. Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis.
Glasner P; Sabisz A; Chylińska M; Komendziński J; Wyszomirski A; Karaszewski B
Restor Neurol Neurosci; 2022; 40(1):35-42. PubMed ID: 35180139
[TBL] [Abstract][Full Text] [Related]
17. Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
Berek K; Hegen H; Hocher J; Auer M; Di Pauli F; Krajnc N; Angermann R; Barket R; Zinganell A; Riedl K; Deisenhammer F; Berger T; Bsteh G
Mult Scler; 2022 Oct; 28(12):1871-1880. PubMed ID: 35652366
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of disease modifying therapy and retinal atrophy in relapsing-remitting multiple sclerosis.
Kabanovski A; Zaslavsky K; Rotstein D; Margolin E
J Neurol Sci; 2023 Mar; 446():120552. PubMed ID: 36774748
[TBL] [Abstract][Full Text] [Related]
19. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
Behbehani R; Abu Al-Hassan A; Al-Salahat A; Sriraman D; Oakley JD; Alroughani R
PLoS One; 2017; 12(2):e0172120. PubMed ID: 28192539
[TBL] [Abstract][Full Text] [Related]
20. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
Button J; Al-Louzi O; Lang A; Bhargava P; Newsome SD; Frohman T; Balcer LJ; Frohman EM; Prince J; Calabresi PA; Saidha S
Neurology; 2017 Feb; 88(6):525-532. PubMed ID: 28077493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
